📰 Therapeutic Vector Evolution News
Page 2 - Therapeutic Vector Evolution News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Therapeutic Vector Evolution. Real-time updates on events, politics, business and more.
November 15, 2023
15.11.2023 - EMERYVILLE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generation AAV vectors currently in human clinical ...
October 30, 2023
Initiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimenAmended INGLAXA protocol to minimize risk of atypical hemolytic uremic syndrome (aHUS) associated with intravenous
September 12, 2023
EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT. Mr. Mehra will succeed August J. Moretti, J.D., who is retiring, and has agreed to serve in an advisory capacity to support Mr. Mehra’s transition. Mr. Mehra wi...
July 30, 2023
4D Molecular Therapeutics, Inc. announced additional positive interim clinical data from the Phase 1 Dose Exploration stage of the 4D-150 Phase 1/2 PRISM clinical trial for patients with wet...
July 29, 2023
Dose response demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental anti-VEGF injections (4 of 4 evaluable...
July 11, 2023
TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) (CEO: David Kirn, MD,
July 11, 2023
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (CEO: David...
June 7, 2023
Reported data from cohort 1 (n=3, 1E15 vg dose) of cystic fibrosis modulator treatment ineligible/intolerant participants with 9-12 months follow-up ...
June 7, 2023
FinancialContent fully hosted finance channel
June 7, 2023
Reported data from cohort 1 of cystic fibrosis modulator treatment ineligible/intolerant participants with 9-12 months follow-up Quality of life outcomes measured by Cystic... | June 9, 2023